Skip to main content

Table 2 Clinical and parasitological efficacy

From: Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial

PCR-corrected failure rates A/L Quinine A/P
Clinical failure rate day 7 0/30 0/35 0/32
Parasitological failure rate day 7 0/30 0/35 0/32
Intention to treat failure rate* day 7 0/30 1/35 (~3%) 0/32
Clinical failure rate day 28 0/30 3/35 (~9%) 1/32 (~3%)
Parasitological failure rate day 28 0/30 3/35 (~9%) 2/32 (~6%)
Intention to treat failure rate* day 28 0/30 7/35 (~20%) 4/32 (~13%)
Recurrent parasitaemia    
Number of patients with recrudescence** (day) 1 (70) 4 (24, 28, 28, 40***) 2 (28, 28)
Number of patients with new infection** (day) 1 (73) 4 (34, 40, 40***, 65) 1 (80)
Number of patients with P. vivax infection (day) 2 (28, 28) 5 (22, 25, 27, 28, 28) 2 (28, 28)
Gametocytaemia    
Number of patients on day 0 1 3 1
Number of patients on day 7 2 10 16
Number of patients on day 28 0 2 0
  1. * lost to follow-up included
  2. **P. falciparum: Genotyping by PCR and RFLP patterns of the MSP-1 and MSP-2 gene
  3. *** One sample showed two different clones on day 40, one of them corresponded to the clone on day 0.